A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors

by | Jul 3, 2024 | Clinical Trials, Ensayos Clínicos - CIMO-01 | 0 comments

JAVIER GARCÍA CORBACHO – ENSAYO CLINICO COMERCIAL – ABBVIE DEUTSCHLAND GMBH & CON K. G